Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Gains from Investment Securities (2022 - 2025)

Historic Gains from Investment Securities for TriSalus Life Sciences (TLSIW) over the last 4 years, with Q3 2025 value amounting to -$2.5 million.

  • TriSalus Life Sciences' Gains from Investment Securities fell 694.92% to -$2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.6 million, marking a year-over-year increase of 3575.51%. This contributed to the annual value of -$11.2 million for FY2024, which is 911.3% down from last year.
  • Latest data reveals that TriSalus Life Sciences reported Gains from Investment Securities of -$2.5 million as of Q3 2025, which was down 694.92% from -$700000.0 recorded in Q2 2025.
  • TriSalus Life Sciences' 5-year Gains from Investment Securities high stood at $9.6 million for Q4 2023, and its period low was -$19.9 million during Q3 2023.
  • Over the past 4 years, TriSalus Life Sciences' median Gains from Investment Securities value was -$260000.0 (recorded in 2022), while the average stood at -$1.6 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first plummeted by 44392.36% in 2023, then surged by 1802727.27% in 2024.
  • Quarter analysis of 4 years shows TriSalus Life Sciences' Gains from Investment Securities stood at -$260000.0 in 2022, then surged by 3796.54% to $9.6 million in 2023, then plummeted by 91.36% to $830000.0 in 2024, then tumbled by 404.1% to -$2.5 million in 2025.
  • Its Gains from Investment Securities stands at -$2.5 million for Q3 2025, versus -$700000.0 for Q2 2025 and $820000.0 for Q1 2025.